FDA Approves Tregzi (Orca-T) as First and Only Precision-Engineered Cell Therapy for Allogeneic Transplant in Adults with Hematological Malignancies
RegulatoryapprovedTregziPositive
AI Analysis
Summary
The FDA approved Tregzi (Orca-T), a precision-engineered cell therapy developed by Orca Bio, for allogeneic transplant in adults with hematological malignancies. The approval marks the first and only therapy in this category.
Outcome Details
FDA approved Tregzi (Orca-T) as first and only precision-engineered cell therapy for allogeneic transplant in adults with hematological malignancies
Importance:9/10
Sentiment:
0.95
FDA approvalcell therapyfirst-in-classhematological malignanciesallogeneic transplant
Read the original article
Published by Drugs.com New Drug Approvals on June 30, 2026 4:06 AM